Pulmonary Function and Respiratory Diseases in Different Genotypes of Alpha-1 Antitrypsin Deficiency

José María Hernández Pérez1, Juan José Suárez Sánchez2, Claudia Viviana López Charrí1, Yolanda Ramallo Fariña3,4,5, José Antonio Pérez Pérez6

1Department of Pulmonology, Hospital Universitario Nuestra Señora de Candelaria [Our Lady of Candelaria University Hospital], Santa Cruz de Tenerife, Canary Islands, Spain
2Faculty of Health Sciences, Universidad de Las Palmas de Gran Canaria [Las Palmas de Gran Canaria University], Canary Islands, Spain
3Foundation of the Canary Islands Health Research Institute (FIISC), Santa Cruz de Tenerife, Spain
4Health Services Research on Chronic Patients Network (REDISSEC), Madrid, Spain
5Research Network on Chronic Disease, Primary Care, and Health Promotion (RICAPPS), Madrid, Spain
6Department of Biochemistry, Microbiology, Cellular Biology and Genetics, Canary Islands, Spain

OBJECTIVE: Respiratory disease is the major cause of morbidity and mortality in patients with alpha-1 antitrypsin deficiency, mainly in homozygous PI*ZZ individuals. However, this association is uncertain in subjects with other deficiency genotypes. The objective of this study was to assess, in the context of alpha-1 antitrypsin deficiency, the existence of further risk factors that have been associated with respiratory diseases.

MATERIAL AND METHODS: Lung function was assessed by spirometry in a sample of 1314 patients with a known genotype for the SERPINA1 gene whose serum alpha-1 antitrypsin levels had been previously determined. Patients with a normal genotype (PI*MM) were compared to 389 patients carrying a deficiency allele.

RESULTS: Statistically significant associations were detected between (i) PI*ZZ genotype and abnormal FEV1 values ($\chi^2 = 26.45; P < .0002$), FEV1/FVC ($\chi^2 = 14.8; P < .02$) or forced mid-expiratory flow 25%-75% ($\chi^2 = 22.66; P < .0009$); (ii) chronic obstructive pulmonary disease and PI*ZZ odds ratio: 26.5; 95% CI: (2.6-265.9); $P < .005$ and or PI*SS genotype odds ratio: 9; 95% CI: (2-40.1); $P < .004$; (iii) prevalence of COPD in PI*MZ subjects and smoking habit ($P < .01$), low body weight ($P < .01$) or older age ($P < .0001$).

CONCLUSION: The PI*ZZ and PI*SS genotypes seem to be associated with the prevalence of chronic obstructive pulmonary disease. Tobacco use, low body weight, and older age are risk factors that increase the probability of prevalence of chronic obstructive pulmonary disease by up to 70% in PI*MZ individuals.

KEYWORDS: Alpha-1 antitrypsin deficiency, spirometry, lung function, chronic obstructive pulmonary disease, respiratory disease

Received: January 12, 2022 Accepted: June 24, 2022 Publication Date: August 8, 2022
MATERIAL AND METHODS

Study Design
This was an observational, cross-sectional, analytic study in which a total of 1510 patients who consecutively attended the respiratory medicine outpatient clinic for any reason were included and analyzed. They were divided into 2 comparable groups: 1 group of subjects with a normal genotyping result (Pi*MM-control group) and another group of subjects with a different genotyping result (Pi*zMM). The objectives of the study were to see if genotypes other than Pi*ZZ have increased in the prevalence of COPD and the percentage of alteration of spirometry values. The study was conducted in accordance with the Declaration of Helsinki. This study was approved by the ethics committee of the Hospital [HGLaPalma_2010_7], and all patients were informed of the study objectives and signed an informed consent. In the case of minors, their parent or guardian signed the consent.

Inclusion criteria were patients who properly performed the spirometry technique, patients who had undergone genotyping of the SERPINA1 gene, patients whose alpha-1 antitrypsin (AAT) levels had been measured via blood clinical chemistry, and patients who expressed their agreement to participate in the study by signing the informed consent form.

Exclusion criteria were patients diagnosed with at least 2 respiratory diseases, patients who could not perform spirometry for various reasons, and patients whose spirometry did not meet the reproducibility criteria.

Patients
After the SERPINA1 gene was genotyped by real-time polymerase chain reaction with HybProbe probes and/or DNA sequencing,[9,10] the patients were divided into 2 groups: those with normal genotyping (Pi*MM; 945 individuals) and those carrying a deficient allele (Pi*S, Pi*Z or rare variants; 389 individuals). Measurement of each patient’s serum AAT levels was performed by immunonephelometry.

Determination of Lung Function by Spirometry
Forced spirometry was performed using the Datospir 600 spirometer (Silbemed®). Each individual performed at least 3 maneuvers in the pre-bronchodilator and post-bronchodilator tests, with a deviation of less than 200 mL in the measurements of forced vital capacity (FVC) and FEV1 established as a reproducibility criterion. Acceptability criteria were determined in the analysis of the curve performed by assessing the start (FEV1 and maximum expiratory flow), the morphology of the flow–volume (FV) curve, the volume–time (VT) curve, and the end with a minimum duration of 6 seconds of forced expiration, following standard quality criteria.11

Four variables were used to define an impaired respiratory function: FEV1, abnormal if less than 80%; FVC, abnormal if below 80%; FEV1/FVC ratio, abnormal if below 70%; forced mid-expiratory flow at 25% and 75% of the pulmonary volume (FEF 25%-75%), defined as abnormal if less than 60%.11

Definition of Respiratory Disease
The following respiratory diseases were diagnosed based on a range of different investigations and tests: bronchial asthma, defined according to the criteria of the Guía Española para el Manejo del Asma [Spanish Asthma Management Guidelines] (GEMA)12; COPD, defined according to the criteria of the Guía Española de Diagnóstico y Tratamiento de la Enfermedad Pulmonar Obstructiva Crónica [Spanish Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease] (GesEPOC)13; sleep apnea–hypopnea syndrome (SAHS), defined according to the criteria of the Spanish guidelines for diagnosis and treatment of SAHS14; obesity hypoventilation syndrome (OHS), also defined according to the Spanish guidelines for SAHS14; non-specific bronchial hyperresponsiveness, defined as the excessive narrowing of the airway lumen in response to physical or chemical stimuli that usually only cause little or no reduction in the lumen, which can be detected, temporarily or permanently, accompanying other situations (exposure to environmental contaminants and irritants, viral infections of the respiratory tract, chronic bronchitis, rhinitis, sarcoidosis, mitral stenosis, bronchopulmonary dysplasia, etc.), or even in apparently healthy subjects.15

In other diseases, small percentages of other pathologies of the respiratory system were grouped, for example, diffuse interstitial lung diseases, bronchiectasis, pulmonary neoplasms, neurological diseases with pulmonary involvement (amyotrophic lateral sclerosis), alterations of the rib cage, non-specific pleural effusions, and pneumothorax.

Statistical Analysis
Qualitative variables were summarized as frequencies and percentages and continuous variables as means and standard deviations (SD). For continuous normal variables, bivariate comparisons between independent samples were made using Student’s t-test or ANOVA depending on the number of groups to compare. Qualitative variables were tested by means of chi-square or Fisher’s exact test, as applicable. To compare the frequency between 2 samples, Z test was used. To study the association of the sample characteristics with the diagnosis of COPD, a multivariate logistic regression was implemented, including the variables with P-value <.1 in the bivariate analysis. Odds ratio (OR) and its 95% CI were obtained as a measure of association and Nagelkerke’s R squared as a measure of goodness of fit. A P-value of <.05 was considered statistically significant. Analyses were performed using the Statistical Package for Social Sciences version 21.0 software (IBM Corp.; Armonk, NY, USA).

RESULTS

Baseline Characteristics
Out of the sample of 1510 patients, 176 were excluded because they did not meet the inclusion criteria. The final study sample consisted of 1334 patients; the majority were...
## Table 1. Baseline Characteristics of the Patients

|                          | No Respiratory Pathology (n = 158) | Asthma (n = 455) | COPD (n = 383) | SAHS/OHS (n = 164) | HBR (n = 85) | Others (n = 89) | Total (n = 1334) | P       |
|--------------------------|----------------------------------|-----------------|----------------|--------------------|-------------|----------------|-----------------|---------|
| Sex, women, n (%)        | 89 (56.3)                        | 286 (62.9)      | 55 (14.4)      | 41 (25)            | 50 (58.8)   | 43 (48.3)      | 564 (42.3)      | <.001   |
| Age, mean (SD)           | 43.6 (15.8)                      | 47.5 (19.3)     | 67.7 (12.4)    | 61.7 (11.8)        | 58 (17.2)   | 65.4 (15.6)    | 564 (15.6)      | <.001   |
| Weight, kg               | 75.6 (17.5)                      | 78.8 (18.2)     | 80.6 (17.4)    | 98 (17.3)          | 83.4 (14.2) | 75.6 (16)      | 81.4 (18.6)     | <.001   |
| BMI, kg/m², mean (SD)    | 27.2 (5.4)                       | 28.7 (6)        | 28.3 (5.8)     | 34.2 (5.9)         | 31 (4.9)    | 28.6 (5.7)     | 29.2 (6.1)      | <.001   |
| Smoking, n (%)           |                                  |                 |                |                    |             |                |                 |         |
| Non-smokers             | 103 (65.2)                       | 299 (65.7)      | 14 (3.7)       | 68 (41.5)          | 50 (58.8)   | 44 (49.4)      | 578 (43.3)      | <.001   |
| Former smokers          | 31 (19.6)                        | 106 (23.3)      | 238 (62.1)     | 66 (40.2)          | 23 (27.1)   | 29 (32.6)      | 493 (37)        |         |
| Smokers                 | 24 (15.2)                        | 50 (11)         | 131 (34.2)     | 30 (18.3)          | 12 (14.1)   | 16 (18)        | 263 (19.7)      |         |
| Genotype, n (%)          |                                  |                 |                |                    |             |                |                 | <.001   |
| Pi*MM                   | 57 (36.1)                        | 334 (73.4)      | 288 (75.2)     | 133 (81.1)         | 63 (74.1)   | 70 (78.7)      | 945 (70.8)      |         |
| Pi*MS                   | 44 (27.8)                        | 73 (16)         | 60 (15.7)      | 26 (15.9)          | 14 (16.5)   | 11 (12.4)      | 228 (17.1)      |         |
| Pi*SS                   | 1 (0.6)                          | 5 (1.1)         | 12 (3.1)       | 0 (0)              | 1 (1.2)     | 1 (1.1)        | 20 (1.5)        |         |
| Pi*MZ                   | 35 (22.2)                        | 30 (6.6)        | 16 (4.2)       | 4 (2.4)            | 4 (4.7)     | 5 (5.6)        | 94 (7)          |         |
| Pi*SZ                   | 10 (6.3)                         | 8 (1.8)         | 2 (0.5)        | 1 (0.6)            | 2 (2.4)     | 2 (2.2)        | 25 (1.9)        |         |
| Pi*SS                    | 2 (1.3)                          | 0 (0)           | 4 (1)          | 0 (0)              | 0 (0)       | 0 (0)          | 6 (0.4)         |         |
| Rare variants           | 9 (5.7)                          | 5 (1.1)         | 1 (0.3)        | 0 (0)              | 1 (1.2)     | 0 (0)          | 16 (1.2)        |         |
| Altered genotype (S o Z), n (%) | 92 (61.7)                        | 116 (25.8)      | 94 (24.6)      | 31 (18.9)          | 21 (25)     | 19 (21.3)      | 373 (28.3)      | <.001   |
| Serum AAT, mg/dL, mean (SD) | 98.1 (27)                        | 125.7 (29)      | 134.9 (34.8)   | 124 (23.3)         | 119.9 (26)  | 134.1 (32)     | 125.1 (31.9)    | <.001   |
| FVC (ml), mean (SD)      | 4043.1 (1053.8)                  | 3591 (1154.1)   | 3021.9 (950.5) | 3599.3 (1051.1)    | 3323.1 (1037.5) | 2691.2 (1144.4) | 3405.6 (1128.7) | <.001   |
| FVC (%), mean (SD)       | 96.4 (12.2)                      | 89 (15.8)       | 70.6 (18.8)    | 83.1 (15.2)        | 88.1 (16.4) | 71.8 (19)      | 82.6 (19)       | <.001   |
| FEV1 (ml), mean (SD)     | 3375 (882.1)                     | 2847.4 (973)    | 1934.4 (767.6) | 2953.8 (855.8)     | 2671.2 (882.6) | 2135.4 (896.6) | 2602.1 (1012)   | <.001   |
| FEV1 (%), mean (SD)      | 104 (13.5)                       | 91.3 (17.2)     | 62.5 (20.8)    | 93.2 (16.5)        | 95.4 (17.7) | 79 (20.4)      | 84.2 (2.3)      | <.001   |
| FEV1/FVC (ml), mean (SD) | 83.6 (6.3)                       | 78.9 (8.9)      | 63.4 (12.3)    | 82.3 (6.7)         | 80.2 (6.6)  | 79.9 (9.1)     | 75.6 (12.3)     | <.001   |
| MEF25-75 (ml), mean (SD) | 3664.7 (1236.6)                  | 2784.2 (1342.3) | 1277 (929.4)   | 3196.7 (1220.1)    | 2630 (1216.8) | 2198.5 (1130.2) | 2457.6 (1443.6) | <.001   |
| MEF25-75 (%), median (SD) | 117.7 (37.6)                     | 95.2 (39.5)     | 50.7 (32)      | 123.3 (45.9)       | 114.8 (59.2) | 105.9 (54.1)   | 90.5 (49)       | <.001   |
| Altered FVC, n (%)       | 16 (10.1)                        | 118 (25.9)      | 263 (68.7)     | 73 (44.5)          | 20 (23.5)   | 52 (64)        | 547 (41)        | <.001   |
| Altered FEV1, n (%)      | 6 (3.8)                          | 106 (23.3)      | 304 (79.4)     | 37 (22.6)          | 15 (17.6)   | 42 (47.2)      | 510 (38.2)      | <.001   |
| Altered FEV1/FVC, n (%)  | 3 (1.9)                          | 65 (14.3)       | 269 (70.2)     | 6 (3.7)            | 6 (7.1)     | 12 (13.5)      | 361 (27.1)      | <.001   |
| Altered MEF25-75, n (%)  | 5 (3.2)                          | 79 (17.4)       | 269 (70.2)     | 7 (4.3)            | 5 (5.9)     | 14 (15.7)      | 379 (28.4)      | <.001   |

Data are presented as median ± SD, n (%).
*Chi-square test.
*ANOVA.
P-value of <.05 was considered statistically significant.
BMI, body mass index; AAT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease; SAHS/OHS, sleep apnoea-hypopnoea syndrome; BHR, non-specific bronchial hyperresponsiveness. FEV1, forced peak expiratory volume in the first second; FVC, forced vital capacity; FEF 25%-75%, forced mid-expiratory flow rate at 25% and 75% of the forced vital capacity; SD, standard deviation.
males (57.7%) and non-smokers, with a mean age of 56.4 and a mean body mass index (BMI) of 29.2 kg/m² (±SD: 6.1). Of these patients, 34.1% were diagnosed with bronchial asthma and 28.4% with COPD. In addition, 27.1% of the patients in the sample had an obstructive pattern (FEV₁/FVC < 70%), and forced vital capacity was abnormal in 41.08%. FEV₁ and MEF 25%-75% were decreased in 38.2% and 28.4% of the patients, respectively. A summary of the other characteristics of the patients is shown in Table 1.

Association Between Genotypes and Lung Function Parameters

In our sample, a statistically significant association was found between the Pi*ZZ genotype and the different lung function parameters, with a chi-squared statistic value for FEV₁ = 26.45, \( P < .0002 \); FEV₁/FVC = 14.8, \( P < .0002 \); and FEF 25%-75% = 22.66, \( P < .0009 \), also Pi*SS genotype and the different lung function parameters, with a chi-squared statistic value for FEV₁ = 34.96, \( P < .024 \); FEV₁/FVC = 23.95, \( P < .001 \); and FEF 25%-75% = 28.79, \( P < .001 \) (Figure 1).

Association Between Genotypes and Respiratory Disease

In Table 2, in studying the association with COPD independently for each of the variables, we observe that being male, being older, and being a smoker or ex-smoker, all genotypes except Pi*MZ, level of ATT, and lung function parameters are more associated with patients with COPD than patients free of the disease.

Multivariate logistic regression shows that Pi*ZZ and Pi*SS were found to be predictors of having COPD with value OR: 26.5; 95% CI: (2.6-265.9); \( P < .005 \) and OR: 9; 95% CI: (2-40.1); \( P < .004 \), respectively (Table 3). The association with COPD of the rest of the variables is maintained once the ORs have been adjusted in the multivariate analysis.

We also wanted to know if there were risk factors for increasing the prevalence of COPD in patients with the Pi*MZ genotype, so we examined patients with COPD in this genotype group to try to determine which variables could predict the increase of the disease. The results showed that patients with a Pi*MZ genotype who are smokers (\( P < .01 \)), underweight (\( P < .01 \)), and older (\( P < .0001 \)) have a likelihood of prevalence of a respiratory disease of more than 70% (Table 4).

**DISCUSSION**

This study assessed lung function in patients with AATD genotypes and identified risk factors for the increase in the prevalence of lung disease. In the vast majority of cases, patients with the Pi*ZZ allele developed lung disease in the form of emphysema, as reported in the literature. Previous studies associated impaired lung capacity assessed by FEV₁ spirometry with both disease severity and survival, particularly when accompanied by smoking, yielding an obstructive pattern characteristic of these patients. In our cohort, this association was statistically significant in the parameters FEV₁, FEV₁/FVC, and FEF 25%-75% (Table 2); our data were in line with previously reported data.

First of all, there was a statistically significant association between the Pi*ZZ genotype and the prevalence of COPD. In this study, patients with Pi*ZZ genotypes and those with rare variants have not been added because rare variants were published in another article in more detail. We also found that the patients with the highest percentage of an obstructive pattern were those with the lowest AAT levels, rendering this association equally statistically significant (\( P < .005 \)). Moreover, we detected another genotype, Pi*SS, which has been linked to an increase in prevalence of COPD (\( P < .004 \)) (Figure 2). In our cohort, no statistically significant association was found between the Pi*MZ genotype and COPD. However, when performing logistic regression to identify the characteristics of patients with the Pi*MZ genotype who had an increased prevalence of COPD, we found a statistically significant association between being

**Figure 1.** Association between AAT genotypes and abnormal lung function parameters: FVC (<80%), FEV₁ (<80%), (FEV₁/FVC <70%), and FEF at 25%-75% of the pulmonary volume (25%-75% <60%). There is a statistically significant association between the Pi*ZZ and Pi*SS genotype and impaired lung function (chi-square test (\( ^* P < .05 \))). AAT, alpha-1 antitrypsin; FVC, forced vital capacity; FEV₁, forced expiratory volume in the first second; FEF, forced mid-expiratory flow.
Table 2. Comparison of Characteristics of Patient’s Presence or Absence of COPD

|                                | No COPD (n = 951) | COPD (n = 383) | P     |
|--------------------------------|-------------------|----------------|-------|
| Sex, women, n (%)              | 509 (53.5)        | 55 (14.4)      | <.001 |
| Age, mean (SD)                 | 51.9 (18.7)       | 67.7 (12.4)    | <.001 |
| Weight, mean (SD)              | 81.7 (19)         | 80.6 (17.4)    | .320  |
| BMI, kg/m², mean (SD)          | 29.6 (6.2)        | 28.3 (5.8)     | <.001 |
| Smoking, n (%)                 |                   |                |       |
| Non-smokers                    | 564 (59.3)        | 14 (3.7)       | <.001 |
| Former smokers                 | 255 (26.8)        | 238 (62.1)     | <.001 |
| Smokers                        | 132 (13.9)        | 131 (34.2)     | <.001 |
| Genotype, n (%)                |                   |                |       |
| Pi*MM                          | 657 (69.1)        | 288 (75.2)     | .262  |
| Pi*MS                          | 168 (17.7)        | 60 (15.7)      | .386  |
| Pi*SS                          | 8 (0.8)           | 12 (3.1)       | .002  |
| Pi*MZ                          | 78 (8.2)          | 16 (4.2)       | .009  |
| Pi*SZ                          | 23 (2.4)          | 2 (0.5)        | .021  |
| Pi*ZZ                          | 2 (0.2)           | 4 (1)          | .039  |
| Rare variant                   | 15 (1.6)          | 1 (0.3)        | .046  |
| Altered genotype (S o Z), n (%)| 279 (29.8)        | 94 (24.6)      | .057  |
| Serum ATT, mg/dL, mean (SD)    | 121 (29.8)        | 134.9 (34.8)   | <.001 |
| FCV (mL), mean (SD)            | 3560.2 (1158)     | 3021.9 (950.5) | <.001 |
| FVC (%), mean (SD)             | 87.5 (16.8)       | 70.6 (18.8)    | <.001 |
| FEV₁ (mL), mean (SD)           | 2871 (973.7)      | 1934.4 (767.6) | <.001 |
| FEV₁ (%), mean (SD)            | 92.9 (18)         | 62.5 (20.8)    | <.001 |
| FEV₁/FVC (mL), mean (SD)       | 80.6 (8.2)        | 63.4 (12.3)    | <.001 |
| MEF25-75(mL), mean (SD)        | 2933 (1337.5)     | 1277 (929.4)   | <.001 |
| MEF25-75 (%), mean (SD)        | 106.5 (45.4)      | 50.7 (32)      | <.001 |
| Altered FVC, n (%)             | 284 (29.9)        | 263 (68.7)     | <.001 |
| Altered FEV₁, n (%)            | 206 (21.7)        | 304 (79.4)     | <.001 |
| Altered FEV₁/FVC, n (%)        | 92 (9.7)          | 269 (70.2)     | <.001 |
| Altered MEF25-75, n (%)        | 110 (11.6)        | 269 (70.2)     | <.001 |

Data are presented as median ± SD or n (%).
Student’s t-test.
*Chi-square test.
Z test.
P-value of <.05 was considered statistically significant.
BMI, body mass index; ATT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease; SAHS/OHS, sleep apnoea-hypopnoea syndrome; BHR, non-specific bronchial hyperresponsiveness; FEV₁, forced expiratory volume in the first second; FVC, forced vital capacity; FEF 25%-75%, forced mid-expiratory flow rate at 25% and 75% of the forced vital capacity; SD, standard deviation.

underweight (P < .05), smoking (P < .0001), and older age (P < .05) and there is a likelihood of an increase in the prevalence of respiratory disease of more than 70%. These results were in line with previous studies conducted by Molloy et al and Cazolla et al in which patients with the Pi*MZ genotype and smokers had poorer lung function and a higher risk of increase in prevalence of COPD than patients with the normal Pi*MM genotype. We believe that the patients having only 1 Z allele would develop disease in more time, have to be heavier smokers, and need to be predisposed (underweight) to develop disease than patients homozygous for the Z allele, who would develop disease

Table 3. Multivariate Logistic Regression for the Presence or Absence of COPD

|                                | Beta   | Wald  | OR (95% CI) | P     |
|--------------------------------|--------|-------|-------------|-------|
| Sex (ref: women)               | 0.93   | 18.5  | 2.53 (1.66-3.86) | <.001 |
| Age                            | 0.07   | 84.0  | 1.07 (1.05-1.08) | <.001 |
| BMI                            | -0.06  | 17.5  | 0.94 (0.91-0.97) | <.001 |
| Smoking habit (ref: non smokers) |       |       |             |       |
| Former smokers                 | 2.7    | 72.3  | 15.41 (8.21-28.95) | <.001 |
| Smokers                        | 3.8    | 121.4 | 46.54 (23.5-92.14) | <.001 |
| Serum ATT                      | 0.01   | 8.8   | 1.01 (1-1.02) | .003  |
| Genotype (ref: Pi*MM)          |        |       |             |       |
| Pi*MS                          | 0.10   | 0.17  | 1.1 (0.69-1.76) | .680  |
| Pi*SS                          | 2.2    | 8.3   | 8.98 (2.01-40.12) | .004  |
| Pi*MZ                          | 0.16   | 0.14  | 1.18 (0.51-2.72) | .704  |
| Pi*SZ                          | 0.10   | 0.01  | 1.1 (0.18-6.81) | .917  |
| Pi*ZZ                          | 3.3    | 7.8   | 26.5 (2.64-265.99) | .005  |
| Rare variant                   | 0.86   | 0.55  | 2.35 (0.24-22.81) | .460  |
| Constant                       | -7.4   | 76.7  | --          | <.001 |

R square of Nagelkerke = 0.563

BMI, body mass index; ATT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease.

Table 4. Multivariate Logistic Regression for the Presence or Absence of COPD in Patients with Genotype Pi*MZ

|                                | Beta   | Z Value | OR (95% CI) | P     |
|--------------------------------|--------|---------|-------------|-------|
| Intercept                      | -2.306 | -1.038  | 0.100 (0.000-7.370) | .299  |
| Smoking                        | 1.110  | 0.498   | 3.034 (1.197-8.882) | .026  |
| Age                            | 0.102  | 3.652   | 1.108 (1.056-1.181) | .000  |
| BMI                            | -0.214 | -2.457  | 0.808 (0.664-0.940) | .014  |

BMI, body mass index; ns: Not significant. Signif. codes: 0 **** 0.001 *** 0.001 ** 0.01 * 0.05. Multivariate Logistic Regression in Patients with Genotype Pi*MZ for the Presence of COPD.
Hobbs et al. reported a great deal of heterogeneity in the COPD, especially in this specific genotype. Unlike ours, up to 30% of subjects did not have lung function is much lower than expected. Furthermore, in this study, results since the proportion of subjects diagnosed with COPD the authors themselves acknowledge that having extracted an important sample size, they found that the genotype Pi*SS weight. Celli et al. showed in their study of the BODE (Body-Conde et al. showed that underweight patients (BMI and rare variants who had developed disease, Tirado-Conde et al. showed in their study of the BODE (Body-Mass Index, Airflow Obstruction, Dyspnea and Exercise Capacity Index) cohort in patients with COPD that patients with both COPD and low weight had a worse prognosis, for which reason weight was included in the BODE scale; having a BMI <21 mg/kg² was scored with 1 point on the scale, while having a BMI is >21 was not scored.

Our study found an association between the Pi*SS genotype and COPD, with the increase in prevalence of respiratory disease being statistically significant (P < .004). This suggests a relationship between the previous genotype and this type of respiratory disease, but due to the size of our sample, we must take it with caution. Other studies have found different results, such as the one carried out by Nakanishi et al. with an important sample size, they found that the Pi*SS genotype did not show an association with COPD, but nevertheless, the authors themselves acknowledge that having extracted their sample of “healthy” subjects may have influenced the results since the proportion of subjects diagnosed with COPD is much lower than expected. Furthermore, in this study, unlike ours, up to 30% of subjects did not have lung function data, which could underestimate the number of patients with COPD, especially in this specific genotype.

Hobbs et al. reported a great deal of heterogeneity in the lung function of patients with AATD, and they believed that, despite the existence of external risk factors, certain added genetic modifiers can also promote the development of lung problems.

Our study has the limitations of a cross-sectional observational study. The temporal sequence of the variables studied could not be established, making it difficult to separate risk factors from prognostic factors. Having extracted our population from a clinical consultation may have influenced our results, although our objective was not to evaluate the incidence or prevalence of AATD but to find possible factors that could favor the increase in prevalence of COPD in patients with different AATD genotypes. The variable of smoking intensity (pack years) was not available and therefore could not be included in the regression study and this may be a factor to take into account in our results. Even so, our data indicated that, in addition to the Pi*ZZ genotype, other genotypes can also increase the prevalence of respiratory disease in the presence of other associated risk factors.

**Figure 2.** Association between AAT genotypes and respiratory disorders. A statistically significant association was found between the genotypes Pi’ZZ and Pi’SS and patients diagnosed with COPD (chi-square test (*P < .05)). SAHS/OHS, sleep apnoea-hypopnoea syndrome; BHR, non-specific bronchial hyperresponsiveness; AAT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease.

In a study of patients with AATD with Pi’ZZ, Pi’SZ and rare variants who had developed disease, Tirado-Conde et al. showed that underweight patients (BMI <18.5 mg/kg²) had a worse prognosis than those of normal weight. Celli et al. showed in their study of the BODE (Body-Mass Index, Airflow Obstruction, Dyspnea and Exercise Capacity Index) cohort in patients with COPD that patients with both COPD and low weight had a worse prognosis, for which reason weight was included in the BODE scale; having a BMI <21 mg/kg² was scored with 1 point on the scale, while having a BMI is >21 was not scored.

Our study found an association between the Pi’SS genotype and COPD, with the increase in prevalence of respiratory disease being statistically significant (P < .004). This suggests a relationship between the previous genotype and this type of respiratory disease, but due to the size of our sample, we must take it with caution. Other studies have found different results, such as the one carried out by Nakanishi et al. with an important sample size, they found that the Pi’SS genotype did not show an association with COPD, but nevertheless, the authors themselves acknowledge that having extracted their sample of “healthy” subjects may have influenced the results since the proportion of subjects diagnosed with COPD is much lower than expected. Furthermore, in this study, unlike ours, up to 30% of subjects did not have lung function data, which could underestimate the number of patients with COPD, especially in this specific genotype.

Hobbs et al. reported a great deal of heterogeneity in the lung function of patients with AATD, and they believed that, despite the existence of external risk factors, certain added genetic modifiers can also promote the development of lung problems.

Our study has the limitations of a cross-sectional observational study. The temporal sequence of the variables studied could not be established, making it difficult to separate risk factors from prognostic factors. Having extracted our population from a clinical consultation may have influenced our results, although our objective was not to evaluate the incidence or prevalence of AATD but to find possible factors that could favor the increase in prevalence of COPD in patients with different AATD genotypes. The variable of smoking intensity (pack years) was not available and therefore could not be included in the regression study and this may be a factor to take into account in our results. Even so, our data indicated that, in addition to the Pi’ZZ genotype, other genotypes can also increase the prevalence of respiratory disease in the presence of other associated risk factors.

**Ethics Committee Approval:** This study was approved by Thics committee of Hospital General de La Palma (HGLaPalma_2010_7).

**Informed Consent:** Written informed consent was obtained from the patients who agreed to take part in the study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept – J.M.H.P., J.A.P.P.; Design – J.M.H.P., J.A.P.P.; Supervision – J.M.H.P.; Funding – J.M.H.P.; Materials – J.M.H.P., J.A.P.P., C.V.L.CH., J.A.P.P.; Data Collection and/or Processing – J.M.H.P., J.J.S.S., C.V.L.CH., Y.R.E.; Literature Review – J.M.H.P., J.J.S.S., C.V.L.CH., Y.R.E., J.A.P.P.; Writing – J.M.H.P., J.A.P.P.; Critical Review – J.M.H.P., J.J.S.S., C.V.L.CH., Y.R.E., J.A.P.P.

**Acknowledgments:** The authors would like to thank Grifols for funding this research project. The authors would also like to thank Jordi Bozzo PhD, CMPP, and Eugenio Rosado, PhD, for their help preparing the manuscript.

**Declaration of Interests:** The authors have no conflict of interest to declare.

**Funding:** This study was funded by Grifols, a manufacturer of plasma alpha-1 antitrypsin. Grifols played no part in the design of the study or in the collection, analysis or interpretation of the study data.

**REFERENCES**

1. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1997; 329(24):1316-1321. [CrossRef]
2. American Thoracic Society, European Respiratory Society, American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818-900. [CrossRef]
3. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency. Pi Z. Acta med Scand 1978; 204(5):345-351. [CrossRef]
4. Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J. 1994; 7(11):1983-1987. [CrossRef]
5. Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989; 111(12):982-991. [CrossRef]
6. Dahl M, Tybjærg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med. 2002; 136(4):270-279. [CrossRef]
7. Ortega VE, Li X, O’Neal WK, et al. The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS. *Am J Respir Crit Care Med.* 2020;201(5):540-554. [CrossRef]

8. Foreman MG, Wilson C, DeMeo DL, et al. Alpha-1 antitrypsin PiMZ genotype is associated with chronic obstructive pulmonary disease in two racial groups. *Ann Am Thorac Soc.* 2017;14(8):1280-1287. [CrossRef]

9. Hernández Pérez JM, Ramos Díaz R, Fumero García S, Pérez Pérez JA. Description of alpha-1-antitrypsin deficiency associated with Pi*Q0ourém allele in la Palma Island (Spain) and a genotyping assay for its detection. *Arch bronconeumol.* 2015;51(1):e1-e3. [CrossRef]

10. Hernández-Pérez JM, Ramos-Díaz R, Pérez JA. Identification of a new defective SERPINA1 allele (Pi*Z(la palma)) encoding an alpha-1-antitrypsin with altered glycosylation pattern. *Respir Med.* 2017;131:114-117. [CrossRef]

11. SEPAR. *Manual separ de procedimientos 3. Sociedad española de neurología y cirugía toracica (SEPAR).* Barcelona: SEPAR; 2002.

12. Guía Española para el manejo del Asma. Luzan; 2020. Available at: http://www.gemaasmal.com.

13. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. *Arch Bronconeumol.* 2017;53(6):324-335. [CrossRef]

14. Lloberes P, Durán-Cantolla J, Martínez-García MÁ, et al. Diagnosis and treatment of sleep apnea-hypopnea syndrome. Spanish Society of pulmonology and thoracic surgery. *Arch Bronconeumol.* 2011;47(3):143-156. [CrossRef]

15. Perpiñá Tordera M, García Río F, Álvarez Gutierrez FJ, et al. Guidelines for the study of nonspecific bronchial hyperresponsiveness in asthma. Spanish Society of pulmonology and thoracic surgery (SEPAR). *Arch Bronconeumol.* 2013;49(10):432-446. [CrossRef]

16. Mostafavi B, Díaz S, Pitulainen E, Stoel BC, Wollmer P, Tanash HA. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency. *Int J Chronic Obstruct Pulm Dis.* 2018;13:3689-3698. [CrossRef]

17. Demeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. *Thorax.* 2007;62(9):806-811. [CrossRef]

18. Thelin T, Sveger T, McNeil TE. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). *Acta Paediatr.* 1996;85(10):1207-1212. [CrossRef]

19. Hernández-Pérez JM, Ramos-Díaz R, Vaquerizo-Pollino C, Pérez JA. Frequency of alleles and genotypes associated with alpha-1 antitrypsin deficiency in clinical and general populations: revelations about underdiagnosis. *Pulmonology.* 2022. [CrossRef]

20. Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. *Am J Respir Crit Care Med.* 2014;189(4):419-427. [CrossRef]

21. Cazzola M, Stolz D, Rogliani P, Materia MG. α(1)-Antitrypsin deficiency and chronic respiratory disorders. *Eur Respir Rev.* 2020;29(155). [CrossRef]

22. Tirado-Conde G, Lara B, Casas F, et al. Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry. *Arch Bronconeumol.* 2011;47(10):495-503. [CrossRef]

23. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med.* 2004;350(10):1005-1012. [CrossRef]

24. Nakanishi T, Forgetta V, Handa T, et al. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. *Eur Respir J.* 2020;56(6):2001441. [CrossRef]

25. Hobbs BD, Cho MH. Why is disease penetration so variable? Role of genetic modifiers of lung function in Alpha-1 antitrypsin deficiency. *Chronic Obstr Pulm Dis.* 2020;7(3):214-223. [CrossRef]